Laura Sibley

Laura Sibley

Project Team Leader 

Public Health England (PHE), UK

 

 

 

 

 

VALIDATE Role:

Network Associate

 

Research Keywords: 

TB, Immunology, Flow cytometry, ELISPOT

 

Biography:

I am currently working in the TB Vaccine Evaluation group at PHE, assessing novel vaccines and therapies and understanding TB disease and pathology using various immunoassays and techniques. I am particularly interested in T-cell responses and the monocyte:lymphocyte ratio. My PhD was conducted at Royal Holloway University of London, developing and understanding Bacillus subtilis spores as a mucosal vaccine adjuvant for TB.

 

Key Publications:

L. Sibley, M. Dennis, C. Sarfas, A. White, S. Clark, F. Gleeson, A. McIntyre, E. Rayner, G. Pearson, A. Williams, P. Marsh, and S. Sharpe, “Route of delivery to the airway influences the distribution of pulmonary disease but not the outcome of Mycobacterium tuberculosis infection in rhesus macaques.,” Tuberculosis (Edinb)., vol. 96, pp. 141–9, Jan. 2016.

A. D. White, C. Sarfas, K. West, L. S. Sibley, A. S. Wareham, S. Clark, M. J. Dennis, A. Williams, P. D. Marsh, and S. A. Sharpe, “Evaluation of the Immunogenicity of Mycobacterium bovis BCG Delivered by Aerosol to the Lungs of Macaques.,” Clin. Vaccine Immunol., vol. 22, no. 9, pp. 992–1003, Sep. 2015.

L. Sibley, R. Reljic, D. S. Radford, J.-M. Huang, H. A. Hong, R. M. Cranenburgh, and S. M. Cutting, “Recombinant Bacillus subtilis Spores Expressing MPT64 Evaluated as a Vaccine Against Tuberculosis in the Murine Model.,” FEMS Microbiol. Lett., Jul. 2014.

A. D. White, L. Sibley, M. J. Dennis, K. Gooch, G. Betts, N. Edwards, A. Reyes-Sandoval, M. W. Carroll, A. Williams, P. D. Marsh, H. McShane, and S. A. Sharpe, “Evaluation of the Safety and Immunogenicity of a Candidate Tuberculosis Vaccine, MVA85A, Delivered by Aerosol to the Lungs of Macaques.,” Clin. Vaccine Immunol., vol. 20, no. 5, pp. 663–72, May 2013.

R. Reljic, L. Sibley, J.-M. Huang, I. Pepponi, A. Hoppe, H. A. Hong, and S. M. Cutting, “Mucosal Vaccination against TB Using Inert Bioparticles.,” Infect. Immun., vol. 81, no. 11, pp. 4071–80, Aug. 2013.